Table 3.36 Calibration curve data of intra-day one of validation.	99
Table 3.37 Calibration curve data of intra-day two of validation.	100
Table 3.38 Calibration curve data of intra-day three of validation.	101
Table 3.39 Calibration curve data of freeze-thaw test of stability.	102
Table 3.40 Calibration curve data of bench-top test of stability.	103
Table 3.41 Calibration curve data of autosampler test of stability.	104
Table 3.42 Calculated Accuracy % based on measured concentration	105
mean for each concentration of standard points.	
Table 3.43 Calculated Accuracy % based on area ratios mean for each	105
concentration of standard points.	
Table 3.44 CV% values of AUC mean of propranolol and sildenafil	107
(internal standard) in mobile phase.	
Table 3.45 CV% values of AUC mean of propranolol and sildenafil	108
(internal standard) in serum blood.	
Table 3.46 Absolute recovery ratios of propranolol in serum.	108
Table 3.47 Absolute recovery ratios of sildenafil citrate (internal)	109
standard) in serum.	
Table 3.48 Glucosamine effect on propranolol AUC, C _{max} , and other	114
pharmacokinetic parameters after an oral dose of 20 mg/kg PRN, PRN	
with GlcN 100 or PRN with GlcN 200 mg/kg in rats. The data are	
presented as mean ± SEM (n=7).	
Table 3.49 Cimetidine and rifampin effect on propranolol AUC, Cmax, and	114
other pharmacokinetic parameters after an oral dose of 20 mg/kg of	
propranolol, propranolol with 5 and 9 mg/kg of cimetidine and rifampin,	
respectively in rats. The data are presented as mean \pm SEM (n=5).	
Table 3.50 P _{eff} , Clearance, and V _d results of propranolol 20 mg/kg,	115
propranolol with 100 and 200 mg/kg GlcN estimated by the	
Nelder-Mead algorithm using the SimCYP program.	